Failure to use new breakthrough treatments for epilepsy.
antiepileptic drug
antiseizure medication
cenobamate
drug resistant
epilepsy
fenfluramine
Journal
Epilepsia
ISSN: 1528-1167
Titre abrégé: Epilepsia
Pays: United States
ID NLM: 2983306R
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
revised:
29
01
2023
received:
08
12
2022
accepted:
27
02
2023
medline:
5
6
2023
pubmed:
2
3
2023
entrez:
1
3
2023
Statut:
ppublish
Résumé
Despite the approval of ~20 additional antiseizure medications (ASMs) since the 1980s, one-third of epilepsy patients experience seizures despite therapy. Drug-resistant epilepsy (DRE) is associated with cognitive and psychiatric comorbidities, socioeconomic impairment, injuries, and a 9.3-13.4 times higher mortality rate than in seizure-free patients. Improved seizure control can reduce morbidity and mortality. Two new ASMs were launched in the United States in 2020: cenobamate for focal epilepsy in adults and fenfluramine for Dravet syndrome (DS). They offer markedly improved efficacy. Cenobamate achieved 21% seizure freedom with the highest dose and decreased tonic-clonic seizures by 93% during maintenance treatment in a randomized clinical trial (RCT). In long-term, open-label studies, 10%-36% of patients were seizure-free for a median duration of ~30-45 months. Fenfluramine treatment in DS reduced convulsive seizure frequency by 56% over placebo at the highest dose, with 8% of patients free of convulsive seizures, and 25% with only one convulsive seizure over 14 weeks. These results were sustained for up to 3 years in open-label extension studies. Mortality was reduced 5-fold. These results are superior to all other approved ASMs, placing these two drugs among the most effective antiseizure therapies. The adverse event profiles resemble those of other ASMs. Despite greater efficacy and similar toxicity, these medications are infrequently used. Two years after US market entry, < 5% of either adults with focal DRE or patients with DS were treated with either cenobamate or fenfluramine. We believe this is a failure of our medical system, resulting from limited knowledge about these drugs stemming partly from the separation of academia from industry; restrictions to access created by health care payors, hospitals, and regulatory agencies; and insufficient post-launch information about the efficacy and safety of these ASMs.
Substances chimiques
Cenobamate
P85X70RZWS
Anticonvulsants
0
Fenfluramine
2DS058H2CF
Types de publication
Randomized Controlled Trial
Journal Article
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1458-1465Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2023 International League Against Epilepsy.
Références
Chen Z, Brodie MJ, Liew D, Kwan P. Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs a 30-year longitudinal cohort study. JAMA Neurol. 2018;75(3):279-86. https://doi.org/10.1001/jamaneurol.2017.3949
Thurman DJ, Logroscino G, Beghi E, Hauser WA, Hesdorffer DC, Newton CR, et al. The burden of premature mortality of epilepsy in high-income countries: a systematic review from the mortality task force of the international league against epilepsy. Epilepsia. 2017;58(1):17-26. https://doi.org/10.1111/epi.13604
Ryvlin P, Cucherat M, Rheims S. Articles Risk of sudden unexpected death in epilepsy in patients given adjunctive antiepileptic treatment for refractory seizures: a meta-analysis of placebo-controlled randomised trials. www.thelancetcom/neurology 2011;10. https://doi.org/10.1016/S1474
Devinsky O, Spruill T, Thurman D, Friedman D. Recognizing and preventing epilepsy-related mortality. Neurology. 2016;86(8):779-86. https://doi.org/10.1212/WNL.0000000000002253
Sperling MR, Barshow S, Nei M, Asadi-Pooya AA. A reappraisal of mortality after epilepsy surgery. Neurology. 2016;86(21):1938-44. https://doi.org/10.1212/WNL.0000000000002700
Löscher W, Klein P. The feast and famine: epilepsy treatment and treatment gaps in early 21st century. Neuropharmacology. 2020;170:108055. https://doi.org/10.1016/j.neuropharm.2020.108055
Perucca E, Brodie MJ, Kwan P, Tomson T. 30 years of second-generation antiseizure medications: impact and future perspectives. Lancet Neurol. 2020;19(6):544-56. https://doi.org/10.1016/S1474-4422(20)30035-1
Kwan P, Brodie M. Early identification of refractory epilepsy. N Engl J Med. 2000;342(5):314-9.
Mattson R, Cramer J, Collins J, et al. Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic-clonic seizures. New England Journal of Medicine. 1985;313(3):145-51.
Halford JJ, Edwards JC. Seizure freedom as an outcome in epilepsy treatment clinical trials. Acta Neurol Scand. 2020;142(2):91-107. https://doi.org/10.1111/ane.13257
Krauss GL, Klein P, Brandt C, Lee SK, Milanov I, Milovanovic M, et al. Safety and efficacy of adjunctive cenobamate (YKP3089) in patients with uncontrolled focal seizures: a multicentre, double-blind, randomised, placebo-controlled, dose-response trial. Lancet Neurol. 2020;19(1):38-48. https://doi.org/10.1016/S1474-4422(19)30399-0
Klein P, Aboumatar S, Brandt C, Dong F., Krauss G.L., Mizne S., Sanchez-Alvarez J.C., Steinhoff B.J., Villanueva V. Long-term efficacy and safety from an open-label extension of adjunctive Cenobamate in patients with uncontrolled focal seizures. Neurology Published online June 15, 2022. doi:https://doi.org/10.1212/WNL.0000000000200792, e989-e998.
Sperling MR, Abou-Khalil B, Aboumatar S, Bhatia P, Biton V, Klein P, et al. Efficacy of cenobamate for uncontrolled focal seizures: post hoc analysis of a phase 3, multicenter, open-label study. Epilepsia. 2021;62(12):3005-15. https://doi.org/10.1111/epi.17091
Rosenfeld WE, Ferrari L, Kamin M et al. Sudden unexpected death in epilepsy during the cenobamate clinical development program. American Epilepsy Society Annual Meeting. December 2-6 2022; Poster 1.293.
Bayat A, Hjalgrim H, Møller RS. The incidence of SCN1A-related Dravet syndrome in Denmark is 1:22,000: a population-based study from 2004 to 2009. Epilepsia. 2015;56(4):e36-9. https://doi.org/10.1111/epi.12927
Cooper MS, Mcintosh A, Crompton DE, McMahon JM, Schneider A, Farrell K, et al. Mortality in Dravet syndrome. Epilepsy Res. 2016;128:43-7. https://doi.org/10.1016/j.eplepsyres.2016.10.006
Lagae L, Sullivan J, Knupp K, Laux L, Polster T, Nikanorova M, et al. Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial. The Lancet. 2019;394(10216):2243-54. https://doi.org/10.1016/S0140-6736(19)32500-0
Nabbout R, Mistry A, Zuberi S, Villeneuve N, Gil-Nagel A, Sanchez-Carpintero R, et al. Fenfluramine for treatment-resistant seizures in patients with Dravet syndrome receiving Stiripentol-inclusive regimens: a randomized clinical trial. JAMA Neurol. 2020;77(3):300-8. https://doi.org/10.1001/jamaneurol.2019.4113
Sullivan J, Lagae L, Devinsky O, et al. Fenfluramine (FINTEPLA) in Dravet syndrome: results of a third randomized, placebo-controlled clinical trial (study 3). American Epilepsy Society Annual Meeting: In; 2020.
Sullivan J, Helen CJ. Raising the bar: fenfluramine sets new treatment standards for Dravet syndrome. Epilepsy and Behavior. 2021;121:1-4. https://doi.org/10.1016/j.yebeh.2021.108061
Sullivan J, Scheffer IE, Lagae L, Nabbout R, Pringsheim M, Talwar D, et al. Fenfluramine HCl (Fintepla®) provides long-term clinically meaningful reduction in seizure frequency: analysis of an ongoing open-label extension study. Epilepsia. 2020;61(11):2396-404. https://doi.org/10.1111/epi.16722
Scheffer I, Devinsky O, Perry M, et al. Efficacy and tolerability of adjunctive FINTEPLA (fenfluramine hydrochloride) in an open-label extension study of Dravet syndrome patients treated for up to 3 years. American Epilepsy Society Virtual Meeting: In; 2020.
Cross JH, Galer BS, Gil-Nagel A, Devinsky O, Ceulemans B, Lagae L, et al. Impact of fenfluramine on the expected SUDEP mortality rates in patients with Dravet syndrome. Seizure: European. J Epilepsy. 2021;93:154-9. https://doi.org/10.1016/j.seizure.2021.10.024
Costa J, Fareleira F, Ascena̧ão R, Borges M, Sampaio C, Vaz-Carneiro A. Clinical comparability of the new antiepileptic drugs in refractory partial epilepsy: a systematic review and meta-analysis. Epilepsia. 2011;52(7):1280-91. https://doi.org/10.1111/j.1528-1167.2011.03047.x
Steinhoff BJ, Ben-Menachem E, Ryvlin P, Shorvon S, Kramer L, Satlin A, et al. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies. Epilepsia. 2013;54(8):1481-9. https://doi.org/10.1111/epi.12212
Ben-Menachem E, Quarato PP, Klein P, et al. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies. American Academy of Neurology: Published online; 2016.
Sperling MR, Klein P, Aboumatar S, Gelfand M, Halford JJ, Krauss GL, et al. Cenobamate (YKP3089) as adjunctive treatment for uncontrolled focal seizures in a large, phase 3, multicenter, open-label safety study. Epilepsia. 2020;61(6):1099-108. https://doi.org/10.1111/epi.16525
SK Life Sciences. Data on file.
Kalilani L, Sun X, Pelgrims B, Noack-Rink M, Villanueva V. The epidemiology of drug-resistant epilepsy: a systematic review and meta-analysis. Epilepsia. 2018;59(12):2179-93. https://doi.org/10.1111/epi.14596
Wu YW, Sullivan J, McDaniel SS, et al. Incidence of dravet syndrome in a US population. Pediatrics. 2015;136(5):e1310-5. https://doi.org/10.1542/peds.2015-1807
Sapkota S, Caruso E, Kobau R, et al. MMWR, Seizure- or Epilepsy-Related Emergency Department Visits Before and During the COVID-19 Pandemic - United States, 2019-2021. 2022 https://www.cdc.gov/coronavirus/2019-ncov/vaccines/stay-up-to-date.html
Jobst BC, Conner KR, Coulter D, Fried I, Guilfoyle S, Hirsch LJ, et al. Highlights from AES2020, a virtual American Epilepsy Society experience. Epilepsy Curr. 2021;21(4):1-8. https://doi.org/10.1177/15357597211018219
Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. The New England Journal of Medicine. 1996;335(9):609-616.
Connolly H, Crary J, McGoon M, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997;337:581-8.
IQVIA Institute for Human Data Science. The Use of Medicines in the U.S.: Spending and Usage Trends and Outlook to 2025.” May 27. https://www.iqvia.com/insights/the-iqvia-institute/reports/the-use-of-medicines-in-the-us. Published online May 27, 2021.
Kluwer W. Medi-Span Price Rx: Online Drug Pricing Tool. https://www.wolterskluwer.com/en/solutions/medi-span/price-rx
Ángel Calleja M, Navarro A, Serratosa JM, Toledo M, Villanueva V, Subías Labazuy S, et al. Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain. Expert Rev Pharmacoecon Outcomes Res. 2022;22(7):1127-36. https://doi.org/10.1080/14737167.2022.2107507
Villanueva V, Serratosa JM, Toledo M, Ángel Calleja M, Navarro A, Sabaniego J, et al. Number needed to treat and associated cost analysis of cenobamate versus third-generation anti-seizure medications for the treatment of focal-onset seizures in patients with drug-resistant epilepsy in Spain. Epilepsy Behav. 2023;139:109054. https://doi.org/10.1016/j.yebeh.2022.109054
Laskier V, Agyei-Kyeremateng KK, Eddy AE, Patel D, Mulheron S, James S, Thomas RH, Sander JW Cost-effectiveness of cenobamate for focal seizures in people with drug-resistant epilepsy. Epilepsia Published online January 10, 2023. https://doi.org/10.1111/epi.17506
Ross J. A survey of anti-seizure medication availability on In-patient hospital formularies in Maryland. Implications for patients with intractable epilepsy and breakthrough seizures. American Epilepsy Society Annual Meeting December 2021; Poster 2.341.
Klein P, Devinsky O, French J, Harden C, Krauss GL, McCarter R, et al. Suicidality risk of newer antiseizure medications. JAMA Neurol. 2021;78(9):1118-27. https://doi.org/10.1001/jamaneurol.2021.2480